|
US6180632B1
(en)
|
1997-05-28 |
2001-01-30 |
Aventis Pharmaceuticals Products Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
|
SI0991628T1
(en)
*
|
1997-05-28 |
2005-06-30 |
Aventis Pharmaceuticals Inc |
QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
|
|
US6159978A
(en)
*
|
1997-05-28 |
2000-12-12 |
Aventis Pharmaceuticals Product, Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
|
US6245760B1
(en)
*
|
1997-05-28 |
2001-06-12 |
Aventis Pharmaceuticals Products, Inc |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
|
US6506769B2
(en)
|
1999-10-06 |
2003-01-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
|
US7101869B2
(en)
|
1999-11-30 |
2006-09-05 |
Pfizer Inc. |
2,4-diaminopyrimidine compounds useful as immunosuppressants
|
|
WO2002014319A2
(en)
|
2000-08-11 |
2002-02-21 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
|
RU2309154C9
(ru)
|
2002-03-27 |
2016-09-27 |
Глэксо Груп Лимитед |
3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
|
|
DE10237423A1
(de)
*
|
2002-08-16 |
2004-02-19 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
|
|
US20050043233A1
(en)
*
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
DE602004000260T2
(de)
|
2003-07-22 |
2006-08-24 |
Arena Pharmaceuticals, Inc., San Diego |
Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
|
|
GT200500008A
(es)
|
2004-01-16 |
2005-08-16 |
|
Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
|
|
PE20090288A1
(es)
|
2007-05-10 |
2009-04-03 |
Smithkline Beecham Corp |
Derivados de quinoxalina como inhibidores de la pi3 quinasa
|
|
EP2508177A1
(en)
|
2007-12-12 |
2012-10-10 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
|
US20110021538A1
(en)
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
EP2241557A1
(de)
|
2009-04-02 |
2010-10-20 |
Æterna Zentaris GmbH |
Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen
|
|
JP5728683B2
(ja)
|
2009-09-04 |
2015-06-03 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
|
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
|
CN101823998B
(zh)
*
|
2010-05-05 |
2015-03-25 |
江苏利田科技股份有限公司 |
一种反应器耦合模拟移动床乙氧基喹啉清洁生产工艺
|
|
DK2624695T3
(en)
|
2010-10-08 |
2016-01-04 |
Nivalis Therapeutics Inc |
NOVEL SUBSTITUTED quinoline-RELATIONS AS S-NITROSOGLUTATHIONREDUKTASEINHIBITORER
|
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
|
AU2011343518B2
(en)
|
2010-12-16 |
2016-11-10 |
Nivalis Therapeutics, Inc. |
Novel substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
|
WO2013135612A1
(en)
|
2012-03-14 |
2013-09-19 |
Bayer Intellectual Property Gmbh |
Substituted imidazopyridazines
|
|
MX371331B
(es)
|
2012-04-24 |
2020-01-27 |
Vertex Pharma |
Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
|
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
ME03336B
(me)
|
2013-03-12 |
2019-10-20 |
Vertex Pharma |
Inhibitori dnk-pk
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
|
AP2015008898A0
(en)
|
2013-06-11 |
2015-12-31 |
Bayer Pharma AG |
Prodrug derivatives of substituted triazolopyridines
|
|
JP6408569B2
(ja)
|
2013-10-17 |
2018-10-17 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
|
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
|
HRP20210319T1
(hr)
|
2014-03-26 |
2021-04-30 |
Astex Therapeutics Ltd. |
Kombinacije inhibitora fgfr i inhibitora igf1r
|
|
RU2715236C2
(ru)
|
2014-03-26 |
2020-02-26 |
Астекс Терапьютикс Лтд |
Комбинации
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
TWI719960B
(zh)
|
2015-02-10 |
2021-03-01 |
英商阿斯迪克治療公司 |
新穎組成物
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
US10022355B2
(en)
|
2015-06-12 |
2018-07-17 |
Axovant Sciences Gmbh |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
|
|
BR112018000728A2
(pt)
|
2015-07-15 |
2018-09-04 |
Axovant Sciences Gmbh |
resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
|
|
WO2017044766A1
(en)
|
2015-09-10 |
2017-03-16 |
Nivalis Therapeutics, Inc. |
Solid forms of an s-nitrosoglutathione reductase inhibitor
|
|
EP3353164B1
(en)
|
2015-09-23 |
2021-11-03 |
Janssen Pharmaceutica, N.V. |
Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
|
|
US11155555B2
(en)
|
2015-09-23 |
2021-10-26 |
Janssen Pharmaceutica Nv |
Compounds
|
|
EP3518931A4
(en)
|
2016-09-27 |
2020-05-13 |
Vertex Pharmaceuticals Incorporated |
METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|